Corcept Therapeutics (CORT) Stock Price, Quote & News

Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also develop...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 327 3270

Website: www.corcept.com

Address:

101 Redwood Shores Parkway, Redwood City, United States

Daniech0514 Feb. 13 at 3:18 AM

$CORT Renaissance tech over 5% ownership. https://ir.corcept.com/node/17396/html

1 · Reply

gucag006 Feb. 12 at 10:06 PM

$CORT Q2 to Gemini AI continues ..... Safety vs. Efficacy Perspectives Interestingly, relacorilant is generally considered to have a cleaner safety profile than Recorlev: Recorlev carries a boxed warning for hepatotoxicity (liver injury) and can cause QT prolongation. Relacorilant was designed to avoid these specific side effects (it does not cause the "off-target" effects of ketoconazole). Despite the better safety profile, the FDA prioritized the certainty of efficacy. They essentially "blocked" relacorilant on the grounds that its effectiveness wasn't robust enough to justify a new drug on the market, whereas they approved Recorlev despite its known toxicities because its efficacy was undeniable.

0 · Reply

gucag006 Feb. 12 at 10:03 PM

$CORT Q2 to Gemini AI: Q2: Is FDA much more strict to relacorilant than recorlev in their perspective NDA and approval or CRL? AI: Based on recent regulatory events, the FDA’s stance on relacorilant (Corcept Therapeutics) has indeed been more restrictive compared to its treatment of Recorlev (Xeris Biopharma). The FDA's Burden of Proof : For Recorlev: The FDA accepted the efficacy data from 166 patients across two trials as sufficient to establish a clear benefit. For Relacorilant: The FDA’s CRL came as a surprise to many because the GRACE trial was technically a success. However, the agency expressed concerns that the data—particularly from the confirmatory GRADIENT trial—did not provide enough evidence to outweigh the risks. This suggests a higher threshold or a lack of conviction in the "clinical meaningfulness" of relacorilant’s blood pressure and glucose improvements compared to Recorlev’s cortisol-lowering consistency.

0 · Reply

gucag006 Feb. 12 at 9:59 PM

$CORT I asked Gemini AI 2 questions: Q1: What's the chance to get the FDA nod on relacorilant for Cushing's syndrome after the FDA meeting to address the issues in CRL? AI: Getting a "nod" from the FDA for relacorilant in Cushing’s syndrome following the recent Complete Response Letter (CRL) is currently facing significant uphill challenges. The "Stumbling Blocks" in the CRL: The FDA’s concerns are not merely administrative; they go to the heart of the drug's safety and effectiveness. The primary issues identified include: - Questionable Effectiveness: - Liver Safety (DILI): - Pre-submission Warnings: Probability of Approval: Scenario Likelihood Timeline Additional Data Analysis Low 12-18 month New Phase 3 Trial High 2 years

1 · Reply

SuperGreenToday Feb. 12 at 6:55 PM

$CORT Share Price: $39.66 Contract Selected: May 15, 2026 $40 Calls Buy Zone: $3.74 – $4.62 Target Zone: $6.08 – $7.43 Potential Upside: 54% ROI Time to Expiration: 91 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

gucag006 Feb. 6 at 11:16 PM

$CORT Okay, to make the naysayers happy, let's forget about Relacorilant for Cushing. - Cushing syndrome is much more prevalent than reported, diagnosed cases (more than 2x prevalence from P4 clinical trials), which can support the rapid growth of both Korlym and Recorlev. - Teva patent case is going to be ruled in Corcept's favor by the federal court any day now. - Korlym's growing sales of $650M in 2024 & $800M-$850M in 2025 (Est.), which should support a SP of $50 alone. - Relacorilant+nab-paclitaxel for PROC: P1/P2/P3 trial tested effective and tolerable; PDUFA=7/11/2026 and nobody on earth is expecting a CRL => Support adding another $50 to SP in 2027. - Dazucorilant for ALS: Will rerun P2 then P3 trials; Looks very promising in ALS survival rate from the last P2 trial => Support adding another $100 to SP in 2028. - Miricorilant for NASH/MASH: 2029 and beyond. Again, the above analysis excludes Relacorilant for Cushing, but I believe it will find a way to eventually get a nod from FDA.

0 · Reply

Nano_Nick Feb. 5 at 1:14 AM

$XERS There is little reason to consider $CORT anymore. Hopefully they do great things this summer and beyond. Cushing market on LOCK between Xeris and Recordati.

2 · Reply

Jdogg85 Feb. 4 at 9:56 PM

$CORT how could anyone trust this idiotic mgmt team after that last debacle? literally told by the FDA not to submit bc they were going to reject it. You can't make this stuff up

0 · Reply

gucag006 Feb. 4 at 8:33 PM

$CORT Don't want to waste too much with you. Have you ever heard of the term "outlier" in the statistical analysis. To conclude that the one case with 50x ULN is irreversible and caused by the drug is ludicrous. I am not making any conclusion here. Let's wait until it is all sorted out between CORT and FDA. GLTA!

1 · Reply

BiotechDrTrader Feb. 4 at 8:05 PM

$CORT I think CORT / TEVA litigation will turn out to be a mixed result and CORT stock will go up post-derisking. The judge involved hasn't been pro or anti-pharmaceutical industry in the past and has applied rigorous legal approach to past judgements, on case by case basis. I think Corcept's enforcement of method of use patents on TEVA was OK given the tricky dosing of korlym, but maybe went too far, and so this ruling will be neither pro-TEVA or pro-Corcept but somewhere in the middle. Once this derisking is out of the way, the market can focus on PROC PDUFA which has a peak sales of $2B+ and so at 3x peak sales multiple could make this company worth $6B just on its own, let alone the hundreds of millions coming in from korlym sales...

0 · Reply

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Feb 9, 2026, 4:54 AM EST - 7 days ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

Feb 4, 2026, 2:24 PM EST - 12 days ago

Allspring Emerging Growth Fund Q4 2025 Performance Review

AMSC ATGE ATI CRS CSTL CVLT CWAN

Feb 4, 2026, 8:42 AM EST - 12 days ago

Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application – Hagens Berman

Jan 30, 2026, 8:32 PM EST - 17 days ago

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing

Jan 30, 2026, 2:20 PM EST - 17 days ago

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application

Jan 30, 2026, 10:36 AM EST - 17 days ago

Corcept shares tumble after FDA letter reveals warnings before drug rejection

Jan 30, 2026, 10:13 AM EST - 17 days ago

Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses

Jan 22, 2026, 11:12 AM EST - 25 days ago

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Jan 22, 2026, 8:13 AM EST - 25 days ago

Corcept's cancer drug meets main goal in late-stage trial

Jan 22, 2026, 8:00 AM EST - 25 days ago

Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Jan 15, 2026, 10:31 AM EST - 4 weeks ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CTRE DCOM DOCN ENVA

Jan 14, 2026, 9:52 PM EST - 4 weeks ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT

Jan 14, 2026, 11:56 AM EST - 4 weeks ago

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman

Jan 13, 2026, 9:43 AM EST - 4 weeks ago

CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Jan 12, 2026, 12:11 PM EST - 5 weeks ago

Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Jan 9, 2026, 3:24 PM EST - 5 weeks ago

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman

Jan 9, 2026, 10:00 AM EST - 5 weeks ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)

Jan 7, 2026, 2:33 PM EST - 5 weeks ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Jan 4, 2026, 7:08 AM EST - 6 weeks ago

Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug

Dec 31, 2025, 4:02 PM EST - 6 weeks ago

Why Corcept Therapeutics stock crashed today and what comes next?

Dec 31, 2025, 12:31 PM EST - 6 weeks ago

Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug

Dec 31, 2025, 8:05 AM EST - 6 weeks ago

US FDA declines to approve Corcept's drug for rare hormonal disorder

Dec 31, 2025, 8:00 AM EST - 6 weeks ago

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

Dec 22, 2025, 11:41 AM EST - 2 months ago

Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?

Nov 4, 2025, 7:26 PM EST - 3 months ago

Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 3 months ago

Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

Oct 28, 2025, 4:05 PM EDT - 3 months ago

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Oct 19, 2025, 5:15 AM EDT - 4 months ago

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Oct 15, 2025, 9:13 AM EDT - 4 months ago

Corcept Transition To New Specialty Pharmacy Well Underway

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Oct 1, 2025, 9:00 AM EDT - 4 months ago

Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics

Sep 29, 2025, 7:11 AM EDT - 5 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ASMB ATRA

Sep 26, 2025, 12:06 PM EDT - 5 months ago

Corcept Primed For An Upside EPS Surprise

Sep 22, 2025, 2:30 PM EDT - 5 months ago

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

Sep 15, 2025, 2:18 PM EDT - 5 months ago

11 fast-growing small-cap stocks that could get a boost from the Fed's next move

AGYS ASTH ENVA GSHD HASI HRMY KNTK

Daniech0514 Feb. 13 at 3:18 AM

$CORT Renaissance tech over 5% ownership. https://ir.corcept.com/node/17396/html

1 · Reply

gucag006 Feb. 12 at 10:06 PM

0 · Reply

gucag006 Feb. 12 at 10:03 PM

0 · Reply

gucag006 Feb. 12 at 9:59 PM

1 · Reply

SuperGreenToday Feb. 12 at 6:55 PM

0 · Reply

gucag006 Feb. 6 at 11:16 PM

0 · Reply

Nano_Nick Feb. 5 at 1:14 AM

$XERS There is little reason to consider $CORT anymore. Hopefully they do great things this summer and beyond. Cushing market on LOCK between Xeris and Recordati.

2 · Reply

Jdogg85 Feb. 4 at 9:56 PM

$CORT how could anyone trust this idiotic mgmt team after that last debacle? literally told by the FDA not to submit bc they were going to reject it. You can't make this stuff up

0 · Reply

gucag006 Feb. 4 at 8:33 PM

1 · Reply

BiotechDrTrader Feb. 4 at 8:05 PM

0 · Reply

Nizmeister Feb. 4 at 7:47 PM

$CORT two important details youre leaving out. First, Recorlev had all patients liver enzymes fully reversed back to normal range with discontinuation while relacorilant had a patient with 50x(!!) ULN and was not reversed even with drug discontinuation per the CRL meaning the drug destroyed that patients liver permanently. $XERS

2 · Reply

gucag006 Feb. 3 at 9:08 PM

$CORT For people who like to hear about and can handle the truth. Apple-to-apple comparison of reported liver injury during their perspective clinical trials (All from Gemini 3 AI): Recorlev (SONICS & LOGICS trials) Peak ALT/AST > 3x ULN - 13% to 15% of patients Peak ALT/AST > 5x ULN - 3% of patients Relacorilant (GRACE & GRADIENT trials) Peak ALT/AST > 3x ULN - 11% of patients Peak ALT/AST > 5x ULN - 4% of patients Trial cohorts sizes Recorlev: SONICS ~ 94, LOGICS ~ 79 (44 randomized) Relacorilant: GRADIENT ~ 137, GRACE ~ 152 (68 randomized) I encourage you to check these #'s using your preferred AI's. Note: ULN = "Upper Limit of Normal"

3 · Reply

gucag006 Feb. 3 at 8:16 PM

$CORT Q4/25 ER will be on 2/25/26 after market close. I am eager to hear what he has to say.

3 · Reply

BiotechDrTrader Feb. 3 at 6:22 PM

$CORT hanging in there despite a mixed day in biotech and a down day in the market overall - can't wait for PROC pdufa

0 · Reply

TymeTryethTroth Feb. 3 at 2:26 PM

$XERS https://seekingalpha.com/article/4865261-xeris-biopharma-strong-recorlev-momentum-and-pipeline-opportunity?share_source=shared_news $BMRN $RARE $LLY $CORT (Comps mentioned in article)

0 · Reply

SuperGreenToday Feb. 2 at 7:37 PM

$CORT Share Price: $40.12 Contract Selected: May 15, 2026 $40 Calls Buy Zone: $4.93 – $6.09 Target Zone: $8.07 – $9.86 Potential Upside: 55% ROI Time to Expiration: 101 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BuyThisOne Feb. 1 at 3:12 PM

$XERS $CORT Increased awarness is good for investors and patients alike. https://csrf.net/

0 · Reply

BuyThisOne Feb. 1 at 3:11 PM

$XERS $CORT Pretty cool story. Seems Strongbridge(Merged with Xeris) followed a similar path with Ketoconazole by purifying it into the levo enantiomer and getting it approved for Cushings syndrome for a relatively low cost. It is important when investing to not only worry about a rising stock price but also the people who's lives have been drastically changed by these medications. The work Corcept and now Xeris is doing to change how these patients are identified allows more people to find a path to having a life they actually want to be alive for. The focus here should be on posting facts instead of attacking each other with outright falsehoods or half-truths. https://kffhealthnews.org/news/how-a-drugmaker-turned-the-abortion-pill-into-a-rare-disease-profit-machine/#:~:text=When%20the%20Food%20and%20Drug,1%2C000%20patients%20in%20the%20U.S.)

0 · Reply

BuyThisOne Feb. 1 at 2:49 PM

$XERS $CORT At the end of the day, the main goal should be access and options for patients needing medicine for these awful conditions. Corcept did a disservice to both themselves and patients by not heeding the FDA's warnings. Patients currently have 3 options and one of them has a generic which is great to help reduce costs over time. This market still has a lot of room to grow as more patients are identified. I could care less about CORT's stock price or their revenue as I am not an investor. It does look like it could 10x from here in 10 years just like XERS will most likely do as well in 5 to 10 years. Maybe split your investment across these 2 if you are worried one way or the other.

1 · Reply

Alon_R Feb. 1 at 1:29 PM

$XERS $CORT Recorlev's upside is substantial, to say the least, because it is a direct cortisol-lowering treatment and therefore a primary therapy, addressing approximately 75–80% of the patient population. The growth potential there is significant. Korlym, by contrast, is a secondary treatment, addressing roughly 20–25% of patients, primarily those who cannot tolerate direct cortisol-lowering therapies due to issues such as liver toxicity or other contraindications. In other words, Recorlev addresses the majority of the treatable Cushing's patient population (roughly ~75–80%), as it directly lowers cortisol and fits first-line treatment paradigms, while Korlym is more naturally positioned for a smaller subset (~25–30%) of patients who cannot tolerate or do not respond to direct cortisol-lowering therapies. And they are not even in competition with each other, the 20-25% that can not tolerate Recorlev/Direct cortisol-lowering, will go naturally to Korlym/etc. Simple equation.

0 · Reply

gucag006 Feb. 1 at 12:31 PM

$XERS $CORT Both Korlym and Recorlev have to be taken continuously. For Recorlev patients, 13% will suffer liver injury, but not Korlym patients. Liver transplant has been reported among Recorlev patients.

2 · Reply

gucag006 Feb. 1 at 12:25 PM

$XERS $CORT (Gemini) 2. Why Korlym is Holding Steady The expected "threat" from Recorlev has been mitigated by a few key factors: Different Mechanisms of Action: Korlym is a cortisol receptor blocker (it stops the hormone from working), while Recorlev is a steroidogenesis inhibitor (it stops the body from making cortisol). Doctors often view them as complementary or for different patient profiles rather than direct "either/or" substitutes. Market Expansion: Increased awareness and better diagnostic tools are identifying more Cushing’s patients than ever before. This "rising tide" is lifting both boats. Generic Buffer: Corcept’s launch of its own authorized generic of Korlym has helped it retain budget-conscious patients who might have otherwise switched to newer or different therapies.

0 · Reply

Market Cap	4.20B
Revenue (ttm)	675.04M
Net Income (ttm)	141.21M
EPS (ttm)	N/A
PE Ratio	43.57
Forward PE	45.51
Profit Margin	20.92%
Debt to Equity Ratio	0.00

Volume	684,500
Avg Vol	2,145,910
Day's Range	N/A - N/A
Shares Out	105.19M
Stochastic %K	50%
Beta	0.25
Analysts	Sell
Price Target	$94.20